LLY vs REPL

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Replimune (REPL) now faces a significantly heightened risk profile following the FDA's second Complete Response Letter (CRL) for RP1 in anti-PD-1-failed melanoma. This crucial setback invalidates the primary near-term catalyst and severely delays commercialization, pushing out any potential 10x growth within the 3-5 year timeframe. The market has reacted with a ~60% stock decline, widespread analy...